These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 31996266)

  • 1. Progression of fibrosing interstitial lung disease.
    Wong AW; Ryerson CJ; Guler SA
    Respir Res; 2020 Jan; 21(1):32. PubMed ID: 31996266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis and Management of Fibrotic Interstitial Lung Diseases.
    Collins BF; Luppi F
    Clin Chest Med; 2021 Jun; 42(2):321-335. PubMed ID: 34024407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior.
    Khine N; Mudawi D; Rivera-Ortega P; Leonard C; Chaudhuri N; Margaritopoulos GA
    Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):231-233. PubMed ID: 33093788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S
    Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
    Singer D; Bengtson LGS; Conoscenti CS; Laouri M; Shetty SS; Anderson AJ; Brown KK
    Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
    [No Abstract]   [Full Text] [Related]  

  • 7. Epidemiology and real-life experience in progressive pulmonary fibrosis.
    Valenzuela C; Cottin V
    Curr Opin Pulm Med; 2022 Sep; 28(5):407-413. PubMed ID: 35938201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive Fibrosing Interstitial Lung Diseases: Prevalence and Characterization in Two Italian Referral Centers.
    Faverio P; Piluso M; De Giacomi F; Della Zoppa M; Cassandro R; Harari S; Luppi F; Pesci A
    Respiration; 2020; 99(10):838-845. PubMed ID: 33264777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease.
    Sarkar P; Avram C; Chaudhuri N
    Expert Rev Respir Med; 2020 Oct; 14(10):1001-1008. PubMed ID: 32567402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
    Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
    Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
    Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
    Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype.
    Nili M; Singer D; Hanna M
    BMC Pulm Med; 2022 Apr; 22(1):153. PubMed ID: 35459138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidelines of the Polish Respiratory Society on the Diagnosis and Treatment of Progressive Fibrosing Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis.
    Piotrowski WJ; Martusewicz-Boros MM; Białas AJ; Barczyk A; Batko B; Błasińska K; Boros PW; Górska K; Grzanka P; Jassem E; Jastrzębski D; Kaczyńska J; Kowal-Bielecka O; Kucharz E; Kuś J; Kuźnar-Kamińska B; Kwiatkowska B; Langfort R; Lewandowska K; Mackiewicz B; Majewski S; Makowska J; Miłkowska-Dymanowska J; Puścińska E; Siemińska A; Sobiecka M; Soroka-Dąda RA; Szołkowska M; Wiatr E; Ziora D; Śliwiński P
    Adv Respir Med; 2022 Oct; 90(5):425-450. PubMed ID: 36285980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study.
    Joung KI; Park H; Park S; Shin JY; Kim YH
    BMC Pulm Med; 2023 Mar; 23(1):98. PubMed ID: 36949407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD.
    Shumar JN; Chandel A; King CS
    J Clin Med; 2021 May; 10(11):. PubMed ID: 34070297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies.
    Li DY; Liu X; Huang JY; Hang WL; Yu GR; Xu Y
    Ther Adv Respir Dis; 2024; 18():17534666241232561. PubMed ID: 38414439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Fibrosing Interstitial Lung Diseases.
    Maher TM; Wuyts W
    Adv Ther; 2019 Jul; 36(7):1518-1531. PubMed ID: 31119691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.
    Hambly N; Farooqi MM; Dvorkin-Gheva A; Donohoe K; Garlick K; Scallan C; Chong SG; MacIsaac S; Assayag D; Johannson KA; Fell CD; Marcoux V; Manganas H; Morisset J; Comes A; Fisher JH; Shapera S; Gershon AS; To T; Wong AW; Sadatsafavi M; Wilcox PG; Halayko AJ; Khalil N; Cox G; Richeldi L; Ryerson CJ; Kolb M
    Eur Respir J; 2022 Oct; 60(4):. PubMed ID: 35273032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the identification and management of progressive pulmonary fibrosis: perspective from Chinese experts.
    Huang H; Wang Q; Xu Z
    Ther Adv Respir Dis; 2024; 18():17534666241288417. PubMed ID: 39415340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be.
    Goos T; De Sadeleer LJ; Yserbyt J; Verleden GM; Vermant M; Verleden SE; Wuyts WA
    J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33807034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.